GENENTA SCIENCE
Genenta Science is a biotechnology company that develops gene transfer therapy for the treatment of cancer tumors. The company is based in Milan, Italy.
GENENTA SCIENCE
Industry:
Biotechnology Clinical Trials Genetics Health Care
Founded:
2014-01-01
Address:
Milano, Lombardia, Italy
Country:
Italy
Website Url:
http://www.genenta.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
33.94 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Qianzhang Investment
Qianzhang Investment investment in Series C - Genenta Science
Club degli Investitori
Club degli Investitori investment in Series C - Genenta Science
Club degli Investitori
Club degli Investitori investment in Series B - Genenta Science
Mediobanca Banca di Credito Finanziario S.p.A.
Mediobanca Banca di Credito Finanziario S.p.A. investment in Series A - Genenta Science
Official Site Inspections
http://www.genenta.com Semrush global rank: 4.92 M Semrush visits lastest month: 1.75 K
- Host name: calvin.dnshigh.com
- IP address: 86.107.36.46
- Location: Voineasa Romania
- Latitude: 45.4167
- Longitude: 23.95
- Timezone: Europe/Bucharest
- Postal: 247750
More informations about "Genenta Science"
ABOUT US | Genenta science
Genenta is a clinical-stage biotechnology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. …See details»
Genenta Science - Crunchbase Company Profile & Funding
Genenta Science closed its last funding round on Dec 31, 2021 from a Post-IPO Secondary round. Who are Genenta Science 's competitors? Alternatives and possible competitors to …See details»
LEADERSHIP | Genenta science
Finance Director. Barbara Regonini is a highly experienced executive with skills in strategic finance, restructuring and reorganization processes, internal controls and corporate governance systems implementation.Prior to joining Genenta, …See details»
Genenta Science - LinkedIn
Genenta Science | 8,943 followers on LinkedIn. Permanent Self-Vaccination Against Cancer | Genenta (Nasdaq: GNTA) is a clinical-stage biotechnology company engaged in the …See details»
Genenta Science - Overview, News & Similar companies - ZoomInfo
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing MILAN, Italy and NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Genenta Science …See details»
2021 FACT SHEET - ir.genenta.com
Genenta Science (NASDAQ: GNTA) - is a clini cal-stage biotech company pioneering the devel-opment of lentivirus-based gene and cell therapy candidates in cancer. Genenta’s proprietary …See details»
Genenta Science Company Profile - Office Locations, Competitors …
Genenta Science $33.92 m in total funding,. See insights on Genenta Science including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Genenta Science and AGC Biologics Enter Development and …
Feb 7, 2023 Genenta had an existing manufacturing services agreement with Molecular Medicine S.p.A.'s facility in Milan, which was subsequently acquired by AGC Biologics in 2020. …See details»
Genenta Science SPA, GNTA:NAQ profile - FT.com - Financial Times
Nov 13, 2024 Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene …See details»
Investor Relations | Genenta Science
May 6, 2024 Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer. Oct 02, 2024 Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. …See details»
Genenta Science S.p.A. (GNTA) - Stock Analysis
Nov 22, 2024 Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in …See details»
Genenta Demonstrated Reprogramming of the Tumor …
Feb 8, 2024 Genenta (www.genenta.com) is a clinical-stage biotechnology company engaged in the development of a proprietary hematopoietic stem cell therapy for the treatment of a variety …See details»
OUR SCIENCE - Genenta
Exploiting our expertise in cell and gene therapy, Genenta have developed a proprietary platform that triggers the production of therapeutics inside tumors, allowing a robust anti-cancer …See details»
Genenta Closes Its Upsized Initial Public Offering of American ...
MILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), a clinical-stage biotechnology company pioneering the development of …See details»
BOARD OF DIRECTORS | Genenta science
Gaurav Shah serves as CEO and President of Rocket Pharma (NASDAQ:RCKT), a publicly traded clinical-stage biotechnology company focused on developing first-in-class gene therapy …See details»
Genenta to take part in gene therapy panel and two virtual …
Jan 5, 2021 MILAN (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene …See details»
GNTA Stock Price Quote | Morningstar
4 days ago Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective” GlobeNewswire Oct …See details»
Genenta Platform | Genenta science
UNITED STATES LaunchLabs – Alexandria Center 430 East 29th Street New York NY 10016See details»
Genenta Announces Pricing of Upsized Initial Public
Dec 15, 2021 Investor Relations - LifeSci Advisors: Genenta Media/Investor Contact: Mary-Ann Chang, CFA: Stefania Mazzoleni, PhD +44 7483 28 48 53 +39 339 709 59 31See details»